Notably, we found that the anti-diabetes drug metformin could rescue bone loss and craniofacial malformation caused by Pck2 ablation via AMPK signaling, thereby indicating a novel strategy to treat bone metabolic dysfunction. The gene discussed is PCK2; the disease is diabetes mellitus.